Rosenman Innovator Catalia raises $4M for patient engagement platform

Home » Blog » Rosenman Innovator Catalia raises $4M for patient engagement platform

Congratulations to Catalia, a 2016 Rosenman Innovator!

Via BusinessWire Catalia Health, a patient care management company that provides an effective, scalable, AI-powered patient engagement platform, announced today the close of its $4 million pre-Series A round. This round, led by Ion Pacific, enables Catalia Health to begin patient rollout, expand into new disease states, grow the company and acquire new customers. The funding bolsters the company’s $2.5 million seed extension and a $1.25 million seed round led by Khosla Ventures.

Catalia Health’s platform combines artificial intelligence, psychology and medical best practices to deliver everyday care to the 117 million patients in the United States managing chronic conditions. Catalia Health’s personal healthcare companion, Mabu, supports patients living with chronic illnesses such as rheumatoid arthritis, late-stage kidney disease and congestive heart failure. Mabu completes daily check-ins using tailored conversations with patients to help them manage care routines, overcome the challenges of isolating illnesses and provide insight to healthcare professionals about patient health, progress and adherence to treatment.

“We’ve seen great traction since the close of our seed extension and this additional funding is a great proof point for the platform we’ve developed and will help us more rapidly expand the number of patients who can benefit from interactions with Mabu,” said Cory Kidd, CEO and founder of Catalia Health. “Ion Pacific, a leading technology-focused merchant bank, is the ideal partner to lead this round as we increase our global footprint. This Lagniappe, or ‘little extra,’ round on top of our seed funding lets the company move even faster than before.”

Khosla Ventures, NewGen Ventures, Abstract Ventures and Tony Ling joined Ion Pacific in the round. This marks Khosla Ventures’ third and NewGen Ventures’ second investment in Catalia Health. In addition to the funding, Catalia Health announces Charles Wu as Director of Product Management. With a deep understanding of provider and patient needs, Wu will oversee the health platform’s roadmap and will work cross functionally to define current and future requirements. Wu brings more than 20 years of product management experience including leading Facebook’s and Twitter’s mobile units.

“Ion Pacific is thrilled to join the Catalia Health team in their quest to improve patient health outcomes and the efficacy of healthcare systems through scalable technology,” said Michael Joseph, Co-CEO of Ion Pacific. “Ion Pacific narrows in on the power of creative and tailored solutions and believes Catalia Health’s approach to healthcare is well-positioned to improve patient outcomes. Moreover, there is tremendous interest among our partners in Asia for this type of company, as interest in RAID (Robotics, AI, IoT, Data) technology continues to grow in Asia. We believe there will be continued strong demand for such innovative technology.”

Catalia Health will begin patient roll out in its first three disease states early 2018. For more information and updates, please visit

About Catalia Health:

Catalia Health is a San Francisco-based patient care management company founded by Cory Kidd, Ph.D in 2014. Catalia Health provides an effective and scalable patient engagement platform for individuals managing chronic disease or taking medications on an ongoing basis. The company’s AI-powered robot, Mabu enables healthcare providers and pharmaceutical companies to better support patients living with chronic illness.

Catalia Health’s care management programs are tailored to increase medication adherence, improve symptom management and reduce the likelihood that a patient is readmitted to the hospital after being discharged.

For more information, please visit and for a full list of investors, please visit

About Ion Pacific:

Ion Pacific is a Hong Kong headquartered merchant bank with additional offices in London, Tel Aviv and the U.S. The firm specialises in global technology investments and bridging the capital and investment flows between Asia, North America, Europe and the Middle East.